Browse
Add New
Tags & Countries
My Library
Account & App
Community
Add New
My Library
Account & App
A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC).
Reply
Use your account to vote, save members, and unlock more features.
No account yet? Register instead
Only moderators have access to these tools. We'll notify you when you're eligible to apply.
Moderator pages contain tools for reviewing reports, content, and administrative settings.
Eligibility is based on participation, quality contributions, guideline adherence, and reputation.
When you qualify, you'll get email or dashboard instructions to submit your application.
Engage, report issues, and help others—strong community contributions improve eligibility.
Essential storage and login support are always on. You can choose whether to allow ads and Google Analytics.
Essential storage and login support are always enabled. Ads can be turned off below.
Comments (0)
No comments yet.